1-20 of 105
Paul M. Barr
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Jan A. Burger, Neil E. Kay, John N. Allan, Paul M Barr, Jacqueline C. Barrientos, Carolyn Owen, Victoria Wang, Hsin-Hui Huang, Lynne Neumayr, Christopher Abbazio, Gabriel S. Krigsfeld, Sneh Mody, Paolo Ghia, Tait D. Shanafelt
Journal: Blood
Blood (2024) 144 (Supplement 1): 4615.
https://doi.org/10.1182/blood-2024-194382
Published: 2024
Journal Articles

Treatment Outcomes of Patients Treated with Venetoclax-Obinutuzumab Therapy Vs Btki Therapies in 1L CLL: An International Real-World Study

Nicole Lamanna, Jennifer R. Brown, Chaitra S. Ujjani, Toby A. Eyre, Beenish Manzoor, Nilanjan Ghosh, Lindsey Roeker, Matthew S. Davids, Catherine C Coombs, Alan P Skarbnik, Brian T. Hill, Hande H. Tuncer, Lori A. Leslie, Joanna M. Rhodes, Isabelle Fleury, Paul M Barr, Nnadozie Emechebe, Nicolas Martinez-Calle, Christopher E. Jensen, Yun Choi, Dureshahwar Jawaid, Laurie K Pearson, Meghan C. Thompson, Steven E Marx, Wendy J. Sinai, Frederick Lansigan, Bita Fakhri, Deborah M. Stephens, Stephen J. Schuster, Michael Coyle, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4625.
https://doi.org/10.1182/blood-2024-205223
Published: 2024
Journal Articles

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

William G. Wierda, Ryan Jacobs, Paul M Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan M. O'Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis A. Carney, Anna Elinder Cambrun, Javier De la Serna, Edith Szafer Glusman, Cathy Zhou, Jutta K. Neuenburg, Lynne Neumayr, Anita Szoke, James P. Dean, Paolo Ghia, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (Supplement 1): 1869.
https://doi.org/10.1182/blood-2024-200936
Published: 2024
Journal Articles

Feasibility of Discontinuation of Bruton's Tyrosine Kinase Inhibitors in Patients with Chronic Lymphocytic Leukemia: A Patient Survey

Deborah M. Stephens, Chris Stewart, Liza Avruch, Catherine C Coombs, Alexey Danilov, Brian T. Hill, Mazyar Shadman, Alina S. Gerrie, Christopher E. Jensen, Marc Hoffmann, Allison M. Winter, Daniel A. Ermann, Paul M Barr, Susan M. O'Brien, Brian Koffman, John C. Byrd
Journal: Blood
Blood (2024) 144 (Supplement 1): 7743.
https://doi.org/10.1182/blood-2024-193298
Published: 2024
Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jeff P. Sharman, Talha Munir, Sebastian Grosicki, Lindsey Roeker, John M. Burke, Christine I Chen, Norbert Grzasko, George Follows, Zoltán Mátrai, Alessandro Sanna, Shuhua Yi, Ru Feng, Vu Minh Hua, Jadwiga Holodja, Wojciech Jurczak, Matthias Ritgen, Lu-Gui Qiu, Francesc Bosch, Catherine C. Coombs, Katherine Bao, Vishalkumar Patel, Bin Liu, Livia Compte, Ananya Guntur, Ying (Denise) Wang, Marisa Hill, Ching Ching Leow, Paolo Ghia, Paul M Barr
Journal: Blood
Blood (2024) 144 (Supplement 1): 886.
https://doi.org/10.1182/blood-2024-198147
Published: 2024
Journal Articles

Ready, AIM, stop: ibrutinib plus venetoclax in MCL

Clinical Trials & Observations
Danielle S. Wallace, Paul M. Barr
Journal: Blood
Blood (2024) 144 (8): 800–802.
https://doi.org/10.1182/blood.2024025021
Published: 2024
Journal Articles

Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL

CME Clinical Trials & Observations
Jennifer A. Woyach, Gabriela Perez Burbano, Amy S. Ruppert, Cecelia Miller, Nyla A. Heerema, Weiqiang Zhao, Anna Wall, Wei Ding, Nancy L. Bartlett, Danielle M. Brander, Paul M. Barr, Kerry A. Rogers, Sameer A. Parikh, Deborah M. Stephens, Jennifer R. Brown, Gerard Lozanski, James Blachly, Sreenivasa Nattam, Richard A. Larson, Harry Erba, Mark Litzow, Selina Luger, Carolyn Owen, Charles Kuzma, Jeremy S. Abramson, Richard F. Little, Shira Dinner, Richard M. Stone, Geoffrey Uy, Wendy Stock, Sumithra J. Mandrekar, John C. Byrd
Journal: Blood
Blood (2024) 143 (16): 1616–1627.
https://doi.org/10.1182/blood.2023021959
Published: 2024
Includes: Supplemental data
Journal Articles

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Paolo Ghia, William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan, Zoë Hunter, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam
Journal: Blood
Blood (2023) 142 (Supplement 1): 633.
https://doi.org/10.1182/blood-2023-187128
Published: 2023
Journal Articles

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

Nilanjan Ghosh, Nicole Lamanna, Toby A. Eyre, Catherine C Coombs, Beenish S Manzoor, Jennifer R. Brown, Hande H. Tuncer, Chaitra S Ujjani, Lori A Leslie, Lindsey E. Roeker, Matthew S Davids, Joanna M. Rhodes, Alan Skarbnik, Nnadozie Emechebe, Isabelle Fleury, Brian T. Hill, Christopher P. Fox, Paul M. Barr, Dureshahwar Jawaid, Wendy J Sinai, Laurie K Pearson, Frederick Lansigan, Yun Choi, Christopher E. Jensen, Stephen J. Schuster, Kaitlin Kennard, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1908.
https://doi.org/10.1182/blood-2023-179198
Published: 2023
Journal Articles

Ilyad: A Phase III Double Blind, Randomized Trial Evaluating Vitamin D (Cholecalciferol) in Patients with Low Tumor-Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab Therapy

Jonathan W. Friedberg, Michael T. Brady, Strawderman Myla, Brad S. Kahl, Izidore S. Lossos, Jonathon B. Cohen, Patrick M. Reagan, Carla Casulo, Barbara L. Averill, Brian K. Link, Paul M. Barr, John P. Leonard, John M. Ashton, Derick R Peterson, Loretta J. Nastoupil
Journal: Blood
Blood (2023) 142 (Supplement 1): 606.
https://doi.org/10.1182/blood-2023-178088
Published: 2023
Journal Articles

Low Dose Rituximab Efficiently Clears Circulating CLL Cells and Maintains Sensitivity to Antibody Dependent Cellular Phagocytosis (ADCP)

Clare B Heffernan, Charles C Chu, Jennifer E Bruno, Christine A Herne, Andrea M Baran, Ronald P Taylor, Paul M. Barr, Michael R. Elliott, Clive S Zent
Journal: Blood
Blood (2023) 142 (Supplement 1): 6548.
https://doi.org/10.1182/blood-2023-175019
Published: 2023
Journal Articles

Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Clive S. Zent, Jeremiah E. Moore, Paige C. Bloom, Charles C. Chu, Jennifer E. Bruno, Christine A. Herne, Andrea M Baran, Sally A. Quataert, Tim R. Mosmann, Ronald P. Taylor, Danielle S. Wallace, Michael R. Elliott, Paul M. Barr
Journal: Blood
Blood (2022) 140 (Supplement 1): 4171–4172.
https://doi.org/10.1182/blood-2022-162858
Published: 2022
Journal Articles

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Robert Stuver, Laure Michaud, Carla Casulo, Ranjana H. Advani, Elizabeth L. Budde, Paul M. Barr, Connie Lee Batlevi, Philip C Caron, Louis S. Constine, Savita Dandapani, Pamela Drullinsky, Jonathan W. Friedberg, Clare Grieve, Audrey Hamilton, Paul A. Hamlin, Richard Hoppe, Steven M. Horwitz, Niloufer Khan, Matthew J. Matasar, Ariela Noy, M.Lia Palomba, Heiko Schoder, David J. Straus, Shreya Vemuri, Joachim Yahalom, Joanna C. Yang, Anas Younes, Andrew D. Zelenetz, Craig H. Moskowitz, Anita Kumar, Alison J. Moskowitz
Journal: Blood
Blood (2022) 140 (Supplement 1): 1756–1758.
https://doi.org/10.1182/blood-2022-156382
Published: 2022
Journal Articles

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥65 Years

Paolo Ghia, Carolyn Owen, Jacqueline C. Barrientos, Paul M. Barr, Anthony R. Mato, Chunxue Shi, Anita Szoke, Chris Abbazio, Gabriel S. Krigsfeld, Jan A. Burger
Journal: Blood
Blood (2022) 140 (Supplement 1): 4159–4161.
https://doi.org/10.1182/blood-2022-163257
Published: 2022
Journal Articles

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

William J Archibald, Anna Barcellos, Jacob Ambrose, Andrew J. Belli, Laura Fernandes, Eric Hansen, Ching-Kun Wang, Paul M. Barr
Journal: Blood
Blood (2022) 140 (Supplement 1): 4142–4143.
https://doi.org/10.1182/blood-2022-170596
Published: 2022
Journal Articles

Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment

Jennifer E. Bruno, Christine A. Herne, Andrea M Baran, Karl R. VanDerMeid, Paul M. Barr, Alyssa R. Williams, Sally A. Quataert, Clive S. Zent, Charles C. Chu
Journal: Blood
Blood (2022) 140 (Supplement 1): 4121–4122.
https://doi.org/10.1182/blood-2022-169403
Published: 2022
Journal Articles

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6640–6641.
https://doi.org/10.1182/blood-2022-163509
Published: 2022
Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Clinical Trials & Observations
Tait D. Shanafelt, Xin Victoria Wang, Curtis A. Hanson, Elisabeth M. Paietta, Susan O’Brien, Jacqueline Barrientos, Diane F. Jelinek, Esteban Braggio, Jose F. Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry Erba, Richard M. Stone, Mark Litzow, Martin Tallman, Neil E. Kay
Journal: Blood
Blood (2022) 140 (2): 112–120.
https://doi.org/10.1182/blood.2021014960
Published: 2022
Includes: Supplemental data
Journal Articles

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

Clinical Trials & Observations
Constantine S. Tam, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon Jackson, Bryone J. Kuss, Carol Moreno, Edith Szafer-Glusman, Kristin Russell, Cathy Zhou, Joi Ninomoto, James P. Dean, William G. Wierda, Paolo Ghia
Journal: Blood
Blood (2022) 139 (22): 3278–3289.
https://doi.org/10.1182/blood.2021014488
Published: 2022
Includes: Supplemental data
Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Clinical Trials & Observations
Xin Victoria Wang, Curtis A. Hanson, Renee C. Tschumper, Connie E. Lesnick, Esteban Braggio, Elisabeth M. Paietta, Susan O’Brien, Jacqueline C. Barrientos, Jose Francisco Leis, Cong Christine Zhang, Steven E. Coutre, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Harry Erba, Richard Stone, Mark R. Litzow, Martin S. Tallman, Tait D. Shanafelt, Neil E. Kay
Journal: Blood
Blood (2021) 138 (26): 2810–2827.
https://doi.org/10.1182/blood.2020010146
Published: 2021
Includes: Supplemental data